Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib

Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.
Latest website image capture
Clouds background image

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed, replacing v3.4.1, indicating a minor site update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-14T13:24:06.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added and Revision: v3.4.0 was removed.
    Difference
    0.0%
    Check dated 2026-02-07T08:54:26.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option and updated metadata with 'Last Update Submitted that Met QC Criteria' and the Revision label to v3.4.0 (replacing v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-24T07:51:15.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page shows a minor version update: Revision: v3.3.4 was added and Revision: v3.3.3 was removed. No observable changes to the study details, layout, or functionality were detected on the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-17T06:28:54.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    The study's Locations section was updated with many new sites across the United States (Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Missouri, New Mexico, New York, Pennsylvania, Texas, Washington), Australia (New South Wales, South Australia, Victoria), Canada (Ontario, Quebec), Italy (Campania, Emilia-Romagna, Piedmont, Sardinia, Tuscany, Veneto), and Russia (Moscow Oblast, Sankt-Peterburg), while several previously listed locations were removed; the revision label updated to v3.3.3 and the HHS Vulnerability Disclosure notice was removed.
    Difference
    1%
    Check dated 2025-12-19T13:59:27.000Z thumbnail image
  7. Check
    89 days ago
    Change Detected
    Summary
    Page revision shows Revision: v3.3.2 added and Revision: v3.3.1 removed, indicating a minor platform update. This change does not affect the study details, eligibility criteria, outcomes, or navigation on the page.
    Difference
    0.0%
    Check dated 2025-11-28T04:17:34.000Z thumbnail image

Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib

Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.